At a glance
- Originator Pfizer
- Class Antineoplastics
- Mechanism of Action Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 25 Jun 2001 Discontinued-Preclinical for Cancer in USA (Unknown route)
- 10 Dec 1996 New profile
- 10 Dec 1996 No-Development-Reported for Cancer in USA (Unknown route)